Multidose optimization simulation of erythropoietin treatment in preterm infants

Pediatric Research

Volumn 71, Issue 4, 2012, Pages 332-337

  Rosebraugh, Matthew R ^a   Widness, John A ^b   Veng Pedersen, Peter ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMOGLOBIN SYNTHESIS; HUMAN; INFANT; NEWBORN ANEMIA; PREMATURITY; PRIORITY JOURNAL; SIMULATION; TREATMENT RESPONSE; VERY LOW BIRTH WEIGHT;

ALGORITHMS; AREA UNDER CURVE; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE, NEONATAL; MODELS, STATISTICAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84857954852     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2011.75     Document Type: Article

References (22)

1. Widness JA. Pathophysiology of anemia during the neonatal period, including anemia of prematurity. Neoreviews 2008;9:e520.
2. Strauss RG. Red blood cell transfusion practices in the neonate. Clin Perinatol 1995;22:641-55.
3. Widness JA, Madan A, Grindeanu LA, Zimmerman MB, Wong DK, Stevenson DK. Reduction in red blood cell transfusions among preterm infants: results of a randomized trial with an in-line blood gas and chemistry monitor. Pediatrics 2005;115:1299-306. (Pubitemid 43843234)
4. Madan A, Kumar R, Adams MM, Benitz WE, Geaghan SM, Widness JA. Reduction in red blood cell transfusions using a bedside analyzer in extremely low birth weight infants. J Perinatol 2005;25:21-5. (Pubitemid 40207649)
5. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol 1996;80:140-8. (Pubitemid 26034856)
6. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006;3:CD004863.
7. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995;84:760-7.
8. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, Lowe LS. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999;20:217-23. (Pubitemid 29363908)
9. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122:383-91.
10. Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 1987;262:5554-62.
11. Freise KJ, Widness JA, Veng-Pedersen P. Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants. J Pharmacol Exp Ther 2010;332:229-37.
12. Kirpalani H, Whyte RK, Andersen C, et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006;149:301-7.
13. Haiden N, Cardona F, Schwindt J, et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thromb Haemost 2005;93:118-23. (Pubitemid 40124265)
14. Veng-Pedersen P, Chapel S, Al-Huniti NH, et al. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 2004;25:149-56. (Pubitemid 38765288)
15. Arif B, Ferhan K. Recombinant human erythropoietin therapy in lowbirthweight preterm infants: a prospective controlled study. Pediatr Int 2005;47:67-71. (Pubitemid 40314614)
16. Avent M, Cory BJ, Galpin J, et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. J Trop Pediatr 2002;48:227-33.
17. Salvad A, Ramolfo P, Escobar M, et al. [Early erythropoietin use for the prevention of anemia in infant premature]. Rev Med Chil 2000;128:1313-7.
18. Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa AA. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity? Eur J Pediatr 2000;159:627-8. (Pubitemid 30469453)
19. Jopling J, Henry E, Wiedmeier SE, Christensen RD. Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital health care system. Pediatrics 2009;123:e333-7.
20. Georgieff MK, Amarnath UM, Landon MB, Mills MM, Ophoven JC. Newborn iron status of infants of diabetic mothers (Idms). Clinical Research 1998;36:224-227.
21. Nelder JA, Mead R. A simplex-method for function minimization. Computer Journal 1965 7:308-313.
22. Veng-Pedersen P. Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 1977 5:513-531.